SCHEMBL4257167

SCHEMBL4257167

O=C1COc2ccc(CCCc3ccccc3)cc2N1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.70
DRD2 P14416 2/20 0.58
DRD4 P21917 1/20 0.58
DRD3 P35462 1/20 0.58
NR3C2 P08235 3/20 0.57
MMP12 P39900 1/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HTR1A P08908 4/20 0.50
HTR1D P28221 3/20 0.50
HTR1B P28222 3/20 0.50
GAA P10253 1/20 0.50
HTR2A P28223 1/20 0.49
SLC6A4 P31645 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4272979 0.94 PARP1 (0.73) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL11006154 0.88 PARP1 (0.70) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL11004751 0.88 PARP1 (0.70) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL11002313 0.87 PARP1 (0.77) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL4258386 0.86 PARP1 (0.73) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL4259329 0.85 PARP1 (0.65) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL21177010 0.85 PARP1 (0.79) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL21207261 0.84 PARP1 (0.74) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL9244955 0.84 PARP1 (0.65) PARP1DRD2DRD4DRD3NR3C2
SCHEMBL4178404 0.84 PARP1 (0.65) PARP1DRD2DRD4DRD3NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 PARP1 4095/4885DRD2 3831/4885DRD4 3359/4885
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 PARP1 1/4885DRD2 4579/4885DRD4 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.